Poolbeg Pharma PLC POLB 001 LPS Trial Data to be Presented at IUIS
16 Novembro 2023 - 4:00AM
RNS Non-Regulatory
TIDMPOLB
Poolbeg Pharma PLC
16 November 2023
Poolbeg Pharma plc
POLB 001 LPS Challenge Trial Data to be Presented at IUIS
POLB 001 - a potential blockbuster immunomodulator
16 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a biopharmaceutical company focussed
on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces that
an abstract highlighting the potential of POLB 001 as a
groundbreaking therapy has been accepted for presentation at the 18
(th) International Congress of Immunology ('IUIS'), to be held 27
November - 2 December 2023 in Cape Town, South Africa.
IUIS is the world's leading conference in the field of
immunology and attracts immunologists from universities, healthcare
providers, independent research organisations and industry leaders.
It serves as a premier platform for the exchange of the latest
cutting-edge discoveries and advancements in immunological
research.
The poster presentation will discuss POLB 001's positive LPS
human challenge trial results. POLB 001 is a potential treatment of
severe influenza and Cytokine Release Syndrome (CRS) associated
with cancer immunotherapies. CRS is a severe inflammatory response,
which may be encountered as a side effect of some therapies,
manifesting a range of symptoms that can rapidly progress to a
severe life-threatening reaction. An effective therapy for CRS
could unlock the benefits of cancer immunotherapies, benefiting
patients and healthcare systems alike.
Title: Inhibition of local and systemic inflammatory responses
by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS
administration in healthy volunteers
Session Date: 1 December 2023
Presentation Time: 12pm - 1pm SAST
Location: Hall 2
Presenter: Digna de Bruin, The Centre for Human Drug
Research
If you would like to meet with Poolbeg Pharma, get in touch at
partnering@poolbegpharma.com
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, said: "The acceptance of this abstract at the upcoming IUIS
conference underscores the potential of POLB 001 as a
groundbreaking therapy. Severe influenza and Cytokine Release
Syndrome associated with cancer immunotherapies are significant
problems and an effective drug that can address these issues would
have a significant impact on global health."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma plc is focussed on the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to fund the development of its robust pipeline of innovative
products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history
of delivering significant shareholder value. The team and Board
have been augmented with strong commercialisation expertise
following the appointment of three former members of the Amryt
Pharma plc leadership team, with the intention of repeating Amryt's
success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets
across cancer immunotherapies, infectious disease, and oral GLP-1
agonists for obesity and other metabolic conditions. It uses a
cost-effective development philosophy to generate high quality
human data to support partnering and further development. Its
AI-led infectious disease programmes analyse unique data from human
challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial
appeal.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKELFFXFLZFBE
(END) Dow Jones Newswires
November 16, 2023 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024